Global Refsum Disease Treatment Market

Refsum Disease Treatment Comprehensive Study by Type (Surgery Therapy, Medication), Application (Hospitals, Clinics, Others), Diagnosis (Physical, Molecular Genetic Examination, Prenatal Screening, Enzyme Analysis, Other Testing) Players and Region - Global Market Outlook to 2030

Refsum Disease Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Refsum Disease Treatment
Refsum disease is a metabolic disorder that causes vision loss, absence of a sense of smell, and a number of other symptoms caused by a number of faulty genes (principally PHYH). The patient suffering from this unable to degrade phytanic acid because of deficient activity of phytanoyl-CoA hydroxylase (PhyH), a peroxisomal enzyme catalyzing the first step of phytanic acid alpha-oxidation. Currently, there two treatments are available for Refsum disease including a strict diet low in phytanic acid and is used for long-term management direct removal from the bloodstream of phytanic acid by a dialysis-type process (plasmapheresis or lipid apheresis).

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Refsum Disease Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Fresenius Kabi (Germany), B. Braun Medical Inc. (United States), Medline Industries, Inc. (United States), Illumina, Inc. (United States), Igenomix, S.L. (Spain), Ceuta Healthcare Limited (United Kingdom), Cochlear Ltd. (Australia) and Sonova (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are William Demant Holding A/S (Denmark), Nurotron Biotechnology Co. Ltd. (United States), Agilent Technologies (United States), Bio-Rad Laboratories, Inc. (United States) and Sequenom (United States).

Segmentation Overview
AMA Research has segmented the market of Global Refsum Disease Treatment market by Type (Surgery Therapy and Medication), Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Refsum Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Diagnosis, the sub-segment i.e. Physical will boost the Refsum Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Government Funding and Improvement in the Regulatory Framework

Market Growth Drivers:
Increasing Prevalence of Refsum Disease and Rise in the Awareness about Refsum Disease Treatment Options

Challenges:
Lack of Healthcare Infrasture in Underdeveloped Countries

Restraints:
Lack of Awareness in Underdevelopment Countries

Opportunities:
Growth in the Healthcare Industry Worldwide and Increasing Research and Development Activities

Market Leaders and their expansionary development strategies
In August 2023, Alexion Pharmaceuticals teams up with patient advocacy groups to develop educational resources and support programs for individuals living with Refsum disease.
In September 2023, Alexion Pharmaceuticals launches a patient support program for VITAL, providing financial assistance and access to medication for eligible patients.


Key Target Audience
Refsum Disease Treatment Providers, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Surgery Therapy
  • Medication
By Application
  • Hospitals
  • Clinics
  • Others
By Diagnosis
  • Physical
  • Molecular Genetic Examination
  • Prenatal Screening
  • Enzyme Analysis
  • Other Testing

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Refsum Disease
      • 3.2.2. Rise in the Awareness about Refsum Disease Treatment Options
    • 3.3. Market Challenges
      • 3.3.1. Lack of Healthcare Infrasture in Underdeveloped Countries
    • 3.4. Market Trends
      • 3.4.1. Increasing Government Funding
      • 3.4.2. Improvement in the Regulatory Framework
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Refsum Disease Treatment, by Type, Application, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Refsum Disease Treatment (Value)
      • 5.2.1. Global Refsum Disease Treatment by: Type (Value)
        • 5.2.1.1. Surgery Therapy
        • 5.2.1.2. Medication
      • 5.2.2. Global Refsum Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Refsum Disease Treatment by: Diagnosis (Value)
        • 5.2.3.1. Physical
        • 5.2.3.2. Molecular Genetic Examination
        • 5.2.3.3. Prenatal Screening
        • 5.2.3.4. Enzyme Analysis
        • 5.2.3.5. Other Testing
      • 5.2.4. Global Refsum Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Refsum Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Fresenius Kabi (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. B. Braun Medical Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Medline Industries, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Illumina, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Igenomix, S.L. (Spain)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ceuta Healthcare Limited (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Cochlear Ltd. (Australia)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sonova (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Refsum Disease Treatment Sale, by Type, Application, Diagnosis and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Refsum Disease Treatment (Value)
      • 7.2.1. Global Refsum Disease Treatment by: Type (Value)
        • 7.2.1.1. Surgery Therapy
        • 7.2.1.2. Medication
      • 7.2.2. Global Refsum Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Refsum Disease Treatment by: Diagnosis (Value)
        • 7.2.3.1. Physical
        • 7.2.3.2. Molecular Genetic Examination
        • 7.2.3.3. Prenatal Screening
        • 7.2.3.4. Enzyme Analysis
        • 7.2.3.5. Other Testing
      • 7.2.4. Global Refsum Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Refsum Disease Treatment: by Type(USD Million)
  • Table 2. Refsum Disease Treatment Surgery Therapy , by Region USD Million (2018-2023)
  • Table 3. Refsum Disease Treatment Medication , by Region USD Million (2018-2023)
  • Table 4. Refsum Disease Treatment: by Application(USD Million)
  • Table 5. Refsum Disease Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 6. Refsum Disease Treatment Clinics , by Region USD Million (2018-2023)
  • Table 7. Refsum Disease Treatment Others , by Region USD Million (2018-2023)
  • Table 8. Refsum Disease Treatment: by Diagnosis(USD Million)
  • Table 9. Refsum Disease Treatment Physical , by Region USD Million (2018-2023)
  • Table 10. Refsum Disease Treatment Molecular Genetic Examination , by Region USD Million (2018-2023)
  • Table 11. Refsum Disease Treatment Prenatal Screening , by Region USD Million (2018-2023)
  • Table 12. Refsum Disease Treatment Enzyme Analysis , by Region USD Million (2018-2023)
  • Table 13. Refsum Disease Treatment Other Testing , by Region USD Million (2018-2023)
  • Table 14. South America Refsum Disease Treatment, by Country USD Million (2018-2023)
  • Table 15. South America Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 16. South America Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 17. South America Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 18. Brazil Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 19. Brazil Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 20. Brazil Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 21. Argentina Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 22. Argentina Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 23. Argentina Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 24. Rest of South America Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 27. Asia Pacific Refsum Disease Treatment, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 31. China Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 32. China Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 33. China Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 34. Japan Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 35. Japan Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 36. Japan Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 37. India Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 38. India Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 39. India Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 40. South Korea Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 41. South Korea Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 42. South Korea Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 43. Taiwan Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 44. Taiwan Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 45. Taiwan Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 46. Australia Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 47. Australia Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 48. Australia Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 52. Europe Refsum Disease Treatment, by Country USD Million (2018-2023)
  • Table 53. Europe Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 54. Europe Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 55. Europe Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 56. Germany Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 57. Germany Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 58. Germany Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 59. France Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 60. France Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 61. France Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 62. Italy Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 63. Italy Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 64. Italy Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 65. United Kingdom Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 68. Netherlands Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 69. Netherlands Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 70. Netherlands Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 71. Rest of Europe Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 74. MEA Refsum Disease Treatment, by Country USD Million (2018-2023)
  • Table 75. MEA Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 76. MEA Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 77. MEA Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 78. Middle East Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 79. Middle East Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 80. Middle East Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 81. Africa Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 82. Africa Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 83. Africa Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 84. North America Refsum Disease Treatment, by Country USD Million (2018-2023)
  • Table 85. North America Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 86. North America Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 87. North America Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 88. United States Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 89. United States Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 90. United States Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 91. Canada Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 92. Canada Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 93. Canada Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 94. Mexico Refsum Disease Treatment, by Type USD Million (2018-2023)
  • Table 95. Mexico Refsum Disease Treatment, by Application USD Million (2018-2023)
  • Table 96. Mexico Refsum Disease Treatment, by Diagnosis USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Refsum Disease Treatment: by Type(USD Million)
  • Table 106. Refsum Disease Treatment Surgery Therapy , by Region USD Million (2025-2030)
  • Table 107. Refsum Disease Treatment Medication , by Region USD Million (2025-2030)
  • Table 108. Refsum Disease Treatment: by Application(USD Million)
  • Table 109. Refsum Disease Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 110. Refsum Disease Treatment Clinics , by Region USD Million (2025-2030)
  • Table 111. Refsum Disease Treatment Others , by Region USD Million (2025-2030)
  • Table 112. Refsum Disease Treatment: by Diagnosis(USD Million)
  • Table 113. Refsum Disease Treatment Physical , by Region USD Million (2025-2030)
  • Table 114. Refsum Disease Treatment Molecular Genetic Examination , by Region USD Million (2025-2030)
  • Table 115. Refsum Disease Treatment Prenatal Screening , by Region USD Million (2025-2030)
  • Table 116. Refsum Disease Treatment Enzyme Analysis , by Region USD Million (2025-2030)
  • Table 117. Refsum Disease Treatment Other Testing , by Region USD Million (2025-2030)
  • Table 118. South America Refsum Disease Treatment, by Country USD Million (2025-2030)
  • Table 119. South America Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 120. South America Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 121. South America Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 122. Brazil Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 123. Brazil Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 124. Brazil Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 125. Argentina Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 126. Argentina Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 127. Argentina Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 128. Rest of South America Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 129. Rest of South America Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 130. Rest of South America Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 131. Asia Pacific Refsum Disease Treatment, by Country USD Million (2025-2030)
  • Table 132. Asia Pacific Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 133. Asia Pacific Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 134. Asia Pacific Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 135. China Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 136. China Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 137. China Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 138. Japan Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 139. Japan Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 140. Japan Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 141. India Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 142. India Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 143. India Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 144. South Korea Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 145. South Korea Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 146. South Korea Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 147. Taiwan Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 148. Taiwan Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 149. Taiwan Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 150. Australia Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 151. Australia Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 152. Australia Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 153. Rest of Asia-Pacific Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 154. Rest of Asia-Pacific Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 156. Europe Refsum Disease Treatment, by Country USD Million (2025-2030)
  • Table 157. Europe Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 158. Europe Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 159. Europe Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 160. Germany Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 161. Germany Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 162. Germany Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 163. France Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 164. France Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 165. France Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 166. Italy Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 167. Italy Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 168. Italy Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 169. United Kingdom Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 170. United Kingdom Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 171. United Kingdom Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 172. Netherlands Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 173. Netherlands Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 174. Netherlands Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 175. Rest of Europe Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 176. Rest of Europe Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 177. Rest of Europe Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 178. MEA Refsum Disease Treatment, by Country USD Million (2025-2030)
  • Table 179. MEA Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 180. MEA Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 181. MEA Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 182. Middle East Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 183. Middle East Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 184. Middle East Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 185. Africa Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 186. Africa Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 187. Africa Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 188. North America Refsum Disease Treatment, by Country USD Million (2025-2030)
  • Table 189. North America Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 190. North America Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 191. North America Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 192. United States Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 193. United States Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 194. United States Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 195. Canada Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 196. Canada Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 197. Canada Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 198. Mexico Refsum Disease Treatment, by Type USD Million (2025-2030)
  • Table 199. Mexico Refsum Disease Treatment, by Application USD Million (2025-2030)
  • Table 200. Mexico Refsum Disease Treatment, by Diagnosis USD Million (2025-2030)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Refsum Disease Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global Refsum Disease Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global Refsum Disease Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 7. South America Refsum Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Refsum Disease Treatment Share (%), by Country
  • Figure 9. Europe Refsum Disease Treatment Share (%), by Country
  • Figure 10. MEA Refsum Disease Treatment Share (%), by Country
  • Figure 11. North America Refsum Disease Treatment Share (%), by Country
  • Figure 12. Global Refsum Disease Treatment share by Players 2023 (%)
  • Figure 13. Global Refsum Disease Treatment share by Players (Top 3) 2023(%)
  • Figure 14. Global Refsum Disease Treatment share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Fresenius Kabi (Germany) Revenue: by Geography 2023
  • Figure 18. B. Braun Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. B. Braun Medical Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Medline Industries, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Medline Industries, Inc. (United States) Revenue: by Geography 2023
  • Figure 22. Illumina, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Illumina, Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Igenomix, S.L. (Spain) Revenue, Net Income and Gross profit
  • Figure 25. Igenomix, S.L. (Spain) Revenue: by Geography 2023
  • Figure 26. Ceuta Healthcare Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 27. Ceuta Healthcare Limited (United Kingdom) Revenue: by Geography 2023
  • Figure 28. Cochlear Ltd. (Australia) Revenue, Net Income and Gross profit
  • Figure 29. Cochlear Ltd. (Australia) Revenue: by Geography 2023
  • Figure 30. Sonova (Switzerland) Revenue, Net Income and Gross profit
  • Figure 31. Sonova (Switzerland) Revenue: by Geography 2023
  • Figure 32. Global Refsum Disease Treatment: by Type USD Million (2025-2030)
  • Figure 33. Global Refsum Disease Treatment: by Application USD Million (2025-2030)
  • Figure 34. Global Refsum Disease Treatment: by Diagnosis USD Million (2025-2030)
  • Figure 35. South America Refsum Disease Treatment Share (%), by Country
  • Figure 36. Asia Pacific Refsum Disease Treatment Share (%), by Country
  • Figure 37. Europe Refsum Disease Treatment Share (%), by Country
  • Figure 38. MEA Refsum Disease Treatment Share (%), by Country
  • Figure 39. North America Refsum Disease Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Fresenius Kabi (Germany)
  • B. Braun Medical Inc. (United States)
  • Medline Industries, Inc. (United States)
  • Illumina, Inc. (United States)
  • Igenomix, S.L. (Spain)
  • Ceuta Healthcare Limited (United Kingdom)
  • Cochlear Ltd. (Australia)
  • Sonova (Switzerland)
Additional players considered in the study are as follows:
William Demant Holding A/S (Denmark) , Nurotron Biotechnology Co. Ltd. (United States) , Agilent Technologies (United States) , Bio-Rad Laboratories, Inc. (United States) , Sequenom (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 223 Pages 79 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Refsum Disease Treatment Market Quantitative research analysis
Global Refsum Disease Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Fresenius Kabi (Germany), B. Braun Medical Inc. (United States), Medline Industries, Inc. (United States), Illumina, Inc. (United States), Igenomix, S.L. (Spain), Ceuta Healthcare Limited (United Kingdom), Cochlear Ltd. (Australia) and Sonova (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Government Funding " is seen as one of major influencing trends for Refsum Disease Treatment Market during projected period 2023-2030.
The Refsum Disease Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Refsum Disease Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Trauma Care Center Comprehensive Study by Facility Type (In-house, Standalone), Trauma Type (Falls, Traffic-Related Injuries, Stab/Wound/Cut, Burn Injury, Brain Injury, Other Injuries), Service Type ...
$ 3350
Nephroblastoma Treatment Comprehensive Study by Drugs (Dactinomycin, Doxorubicin,, Vincristine, Cyclophosphamide, Etoposide), Treatment (Surgery, Chemotherapy, Radiation therapy), End-users (Hospital...
$ 3750
Staphylococcal Infection Drugs Comprehensive Study by Type (Beta-lactams, Peptides, Quinolones, Others), Application (Hospital, Pharmacy, Others), Treatment (Antibiotics, Wound Drainage, Device Remov...
$ 3450
Hepatorenal Syndrome Treatment Comprehensive Study by Type (Type 1 Hepatorenal Syndrome, Type 2 Hepatorenal Syndrome), Treatment (Therapeutics (Terlivaz, Glypressin, Lucassin, Hepatoren), Surgical Tr...
$ 3750
Heatstroke Treatment Comprehensive Study by Type (Exertional Heat Stroke, Non-Exertional Heat Stroke), Drugs (Dantrolene, Midazolam, Clonidine, Meperidine, Others), Route of Administration (Oral, Par...
$ 3750
Circle Acute Ischemic Stroke Comprehensive Study by Type (Thrombotic Ischemic Stroke, Embolic Ischemic Stroke), Treatment (Thrombolytic Therapeutics, Antihypertensive Therapeutics, Antiplatelet Thera...
$ 3750